Urinary bladder cancer (UBC) is the sixth most common type of cancer in the United States, with approximately 67,000 new cases and 14,000 deaths from the disease in 2007 (ref. 1) . Cigarette smoking and occupational exposure to specific carcinogens are the strongest known risk factors for UBC. Familial clustering of UBC cases suggests that there is a genetic component to the risk of the disease [2] [3] [4] . Segregation analyses have suggested that this component consists of many genes, each conferring a small risk 5 . Epidemiological studies have evaluated potential associations between variants in candidate genes and UBC, but the results have in many cases been difficult to replicate. Recently, genome-wide association (GWA) studies have led to discoveries of variants in the human genome that confer risk of common diseases, including cancers [6] [7] [8] [9] [10] . To search for loci associated with risk of UBC, we carried out a GWA analysis on Icelandic and Dutch UBC cases and controls, using the Illumina Infinium Whole-Genome Genotyping microarray technology.
We genotyped 525 cases and 32,504 controls from Iceland, as well as 1,278 cases and 1,832 controls from The Netherlands, on the HumanHap300/HumanCNV370-duo BeadChips ( Table 1) . After removing SNPs failing quality control checks, we tested 302,140 SNPs for association with UBC. The results were adjusted for relatedness between individuals and for potential population stratification using the method of genomic control. With this sample size, the combined IcelandNetherlands GWA study has an 88% power to achieve a genome-wide significant result for a variant with an OR of 1.3 and a minor allele frequency of 50%. The power drops to 22% for an OR of 1.2 and the same frequency. No single SNP reached our genome-wide significance threshold (P o 1.6 Â 10 À7 ; corresponding to 0.05/302,140) in either the combined or the individual analysis of the Icelandic or Dutch GWA sample sets (for quantile-quantile plots, see Supplementary Fig. 1 online). The ten most significant SNPs (all P o 5 Â 10 À5 ) were genotyped using Centaurus single track assays in an additional 2,165 UBC cases and 3,800 controls from seven follow up groups, all of European ancestry ( Table 1) . The associations of each of these SNPs in the initial GWA scans, the joint follow-up groups and the combined analysis of all groups are listed in Supplementary Table 1 online. The strongest association with UBC, reaching genome-wide significance in the overall analysis of the discovery and follow-up groups, was observed for the T allele of rs9642880 at 8q24.21 (combined All P values shown are two-sided. Shown are the corresponding numbers of cases and controls (N), allelic frequencies of variants in affected and control individuals, and the allelic odds ratio (OR) with P values based on the multiplicative model.
a Results presented for Iceland and the Netherlands were individually adjusted by the method of genomic control (Supplementary Methods). b For the combined study populations, the reported control frequency was the average, unweighted control frequency of the individual populations, and the OR and P value were estimated using the Mantel-Haenszel model. Table 2) . Of the ten SNPs analyzed, only rs9642880 and rs710521 were nominally significant (P o 0.05) in the combined analysis of the follow-up groups (Supplementary Table  1) , both reaching genome-wide significance in the combined analysis and showing no heterogeneity between the ORs of the nine study groups (P het ¼ 0.69 and 0.77, respectively) ( Table 2) . From the initial genome-wide association scan, two markers (rs12547643 and rs4733677) close to rs9642880 on chromosome 8q24.21 were nominally associated with UBC (P o 0.01). When results for these markers were analyzed in the nine combined groups, only rs4733677[T] was significantly associated with UBC (P ¼ 7.15 Â 10 -6 ) whereas rs12547643[A] was not (P ¼ 0.078). After adjustment for the effect of rs9642880, rs4733677 [T] was no longer significant (P ¼ 0.15). To investigate the mode of inheritance more carefully, we computed the genotype-specific OR for rs9642880. Results from all groups combined demonstrated that the association of rs9642880[T] to UBC did not deviate from the multiplicative model (P ¼ 0.76). Relative to the noncarriers, heterozygous and homozygous carriers of the risk allele T had ORs of 1.22 and 1.49, respectively. Assuming that the frequency of the allele is 45%, that is, the average of its frequency in all the populations studied ( Table 2) , then individuals homozygous for rs9642880 (TT) represent B20% of the population. The estimated population attributable risk of rs9642880[T] is 17%.
The SNP rs9642880 is located in the LD block immediately adjacent to the MYC oncogene (encoding c-Myc) and only 30 kb upstream of it ( Fig. 1) . MYC is the only known gene close to rs9642880, but a predicted gene, BC042052, is also in the same region ( Supplementary  Fig. 2 online) . We genotyped samples from seven of the nine study groups (all populations except those from Sweden and Spain) for two known missense mutations in MYC (G175C, encoded by rs4645960, and N26S, encoded by rs4645959) but found no association with UBC. rs4645960[T] was very rare, with only two cases in the c-Myc is a nuclear phosphoprotein involved in transcriptional regulation. The normal function of c-Myc involves growth regulation, cell differentiation and apoptosis, and its deregulation is associated with malignant growth 11 . Altered expression, methylation and/or copy number variations at 8q24 have been found in bladder tumors, suggesting that c-Myc may have a role in tumor formation 12 . The LD block of rs9642880 has been shown to contain an evolutionarily conserved 1.6-kb insulator element (B2.5 kb upstream of the MYC transcription initiation site) 13 as well as predicted transcription factor binding sites 14 . We have previously measured the expression of 23,720 transcripts using an Agilent microarray and RNA from both adipose tissue and blood for 674 and 1,002 Icelandic individuals, respectively 15 . Of those individuals, 602 with adipose tissue and 744 with blood have been genotyped with the HumanHap300 chip. We used this dataset to investigate the correlation between the rs9642880[T] and MYC expression. No significant correlation was observed between MYC mRNA expression and the number of copies of the T allele of rs9642880 carried, either in whole blood or in adipose tissue (P ¼ 0.86 for whole blood and P ¼ 0.74 for adipose tissue). However, it should be noted that these data are not conclusive, as other regulatory mechanisms for MYC expression might be present in urothelial tissue.
The second strongest signal in the combined analysis was observed for rs710521[A] on chromosome 3q28 (OR ¼ 1.19, P ¼ 1.15 Â 10 À7 ; Table 2 ). The association of rs710521[A] to UBC did not deviate from the multiplicative model (P ¼ 0.70), and the estimated population attributable risk of rs710521[A] was 23%. The ORs for heterozygous and homozygous carriers of the risk allele T were 1.19 and 1.41, respectively, relative to the risk of noncarriers. With the average frequency of the risk allele in all the study populations at 73% ( Table 2) , 53% of the population may be homozygous carriers of rs710521 [A] . No significant interaction was observed between the effects of rs9642880 and rs710521 (P ¼ 0.23). rs710521 is located in an LD block that overlaps the TP63 gene (encoding tumor protein p63), and no other gene is found in this block. TP63 has strong homology with the tumor suppressor gene TP53 and with the TP73 gene that encodes the p53-related protein p73. Like p53, p63 regulates cell-cycle arrest and is involved in apoptosis. It is involved in the normal development of stratified epithelia, including urothelium, and is possibly associated with urothelial differentiation 16 . TP63 expression is often lost in urothelial tumors, and it has been suggested that TP63 may play a critical role in the progression of urothelial neoplasia 17 . We did not observe any significant correlation between TP63 mRNA expression and the number of copies of the A allele of rs710521 carried, in whole blood from 741 individuals and in adipose tissue from 601 individuals (P ¼ 0.58 for whole blood and P ¼ 0.40 for adipose tissue). GWA studies have repeatedly reported cancer-associated variants on 8q24, 200-700 kb proximal to rs9642880 and MYC. We and others found SNPs at 8q24.21 to be strongly associated with prostate cancer (rs1447295, rs6983267 and rs16901979) 6, 18, 19 . Subsequently, rs6983267 was also shown to associate with colorectal cancer 10 and, most recently, rs13281615 has been shown to associate with breast cancer 9 . These four variants are dispersed over a 500-kb region (Fig. 1) and are in weak LD with each other and with rs9642880 ( Table 3) . We did not find any association between these four SNPs and UBC in the combined study groups (Table 3) . Moreover, we found no association between rs9642880 and prostate, breast, colorectal or lung cancer in Icelandic case-control samples (Supplementary Table 2 online). At present, it is not known how these variants at 8q24 affect cancer risk, but the proximity of MYC suggests that it may be implicated in this process. The UBC variant described here is closer to MYC than any of the other known cancer-associated variants, as rs9642880 is located in the LD block adjacent to MYC and only 30 kb upstream of it (Fig. 1) .
Information on stage and grade was available for seven of the nine groups. On the basis of this information, we classified the UBC cases into individuals with a good prognosis ('low risk': tumor confined to the bladder mucosa and not poorly differentiated) or individuals with a considerable risk of tumor progression ('high risk': tumor invasion in or beyond the lamina propria or poorly differentiated) (see Methods). We and others have recently found an association between a variant in the nicotinic acetylcholine receptor gene cluster on 15q24 and nicotine addiction, smoking behavior, lung cancer and peripheral arterial disease [20] [21] [22] [23] . As smoking is a strong risk factor for UBC, we tested the reported smoking-associated variant, rs1051730, in all the nine UBC case-control groups, but found no association between the risk allele and disease (combined OR ¼ 1.03, P ¼ 0.26). We observed no difference in the frequencies of rs9642880[T] on chromosome 8 or rs710521[A] on chromosome 3 between ever-smoking and never-smoking cases (P ¼ 0.47 and P ¼ 0.55, respectively). Similarly, analysis of the Icelandic and Dutch controls showed that the results observed for rs9642880 and rs710521 cannot be explained by an association of these SNPs to smoking initiation or smoking quantity. rs9642880[T] and rs710521[A] did not correlate with age at diagnosis (data not shown). We observed a nominally significant difference in the frequency of rs710521[A] on chromosome 3 between male and female cases (combined OR ¼ 1.14, P ¼ 0.049), with frequency in males being greater than females; no difference was observed for rs9642880 (P ¼ 0.13).
Here we describe two sequence variants, on chromosomes 8q24 and 3q28, associated with UBC in nine study groups of European descent. The strongest variant is on chromosome 8q24.21, only 200 kb downstream of a 500-kb region previously reported to associate with three other cancer types. Clustering of independent cancer-associated variants in this region suggests the existence of a common molecular mechanism of susceptibility. Unlike the variants reported in prostate, colorectal and breast cancer, rs9642880 is located in the LD block adjacent to and only 30 kb upstream of MYC gene. Functional studies of this region are needed to understand the mechanism by which these variants affect carcinogenesis.
METHODS
Subjects. Nine study populations were used in this work: two discovery populations (Iceland and The Netherlands) and seven follow-up sample sets. The Icelandic sample set consists of 525 cases and 32,504 controls, and the Dutch sample set consists of 1,278 cases and 1,832 controls. Follow-up genotyping was done in sample sets from Leeds, UK (724 cases and 530 controls); Torino, Italy (328 cases and 389 controls); Brescia, Italy (181 cases and 192 controls); Leuven, Belgium (197 cases and 379 controls); Stockholm, Sweden (349 cases and 930 controls); Zaragoza, Spain (173 cases and 859 controls) and an Eastern European sample set obtained from the German Cancer Research Center (DKFZ) in Heidelberg (213 cases and 521 controls). All participants gave informed consent and the studies were approved by the appropriate institutional review boards and/or ethics committees. Detailed description of the study populations is provided in Supplementary Methods online.
Genotyping. Samples from Iceland and The Netherlands were used for GWA study and were assayed with either the Infinium HumanHap300 or HumanCNV370 SNP chips (Illumina). The analysis was restricted to 302,140 SNPs that passed quality filters and were deemed usable on the basis of yield, Hardy-Weinberg equilibrium and consistency in genotype frequencies between the two arrays. All samples had call rates above 98%. All follow-up genotyping was carried out by applying single track Centaurus assays (Nanogen). We evaluated the quality of the Centaurus SNP assays by genotyping each assay in Association analysis. For the association analysis, we used a likelihood procedure described in a previous publication 24 and implemented in the NEMO software. An attempt was made to genotype all individuals, and all SNPs reported had a yield that was higher than 95% in every study group. SNPs rs4645960 and rs16901979 are not part of the HumanHap300 or HumanCNV370-duo chips. For these SNPs, a subset of the large Icelandic control set as well as all Icelandic cases and all individuals from the other study groups were genotyped by single track assays. We tested the association of an allele with UBC using a standard likelihood ratio statistic that, if the subjects were unrelated, would have asymptotically a w 2 distribution with 1 degree of freedom under the null hypothesis. Allelic frequencies rather than carrier frequencies are presented for the markers in the main text. Allele-specific ORs and associated P values were calculated assuming a multiplicative model for the two chromosomes of an individual 25 . Results from multiple case-control groups were combined using a Mantel-Haenszel model 26 in which the groups were allowed to have different population frequencies for alleles and genotypes but were assumed to have common relative risks.
Correction of the GWA studies by genomic control. To adjust for possible population stratification and the relatedness amongst individuals, we divided the w 2 test statistics from the individual scans using the method of genomic control 27 , that is, the 302,140 w 2 test statistics were divided by their means, which were 1.04 and 1.075 for Iceland and The Netherlands, respectively. Supplementary Figure 1 is a quantile-quantile (Q-Q) plot of the w 2 statistics, before and after adjustment, against the w 2 distribution.
Correlation between genotype and MYC expression in whole blood and adipose tissue. MYC expression was analyzed in whole blood and adipose tissue from 744 and 602 Icelandic individuals, respectively, and correlated with rs9642880 genotype status. Collection of whole blood and adipose tissue samples, mRNA isolation and expression profiling was described previously 15 . Expression changes between two samples were quantified as mean logarithm (log 10 ) expression ratio (MLR), that is, expression ratios compared to background-corrected intensity values for the two channels for each spot on the arrays 28 . The hybridizations went through the standard quality control process of checking signal-to-noise ratio, reproducibility and accuracy at spike-in compounds. We tested the correlation between MLR for MYC and the genotypes of rs9642880 by regressing the MLRs on the number of copies of the at-risk T allele of rs9642880, adjusting for age, sex and, for whole blood, the differential blood cell count. All P values were adjusted for relatedness of the individuals by simulating genotypes through the Icelandic genealogy as previously described 29 . We used MYC and TP63 probes to test the expression of MYC and TP63, respectively (see Accession codes section below). Accession codes. GenBank: MYC, NM_002467; TP63, NM_003722.
Note: Supplementary information is available on the Nature Genetics website.
